These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30135030)

  • 1. Etifoxine impairs neither alertness nor cognitive functions of the elderly: A randomized, double-blind, placebo-controlled crossover study.
    Deplanque D; Machuron F; Waucquier N; Jozefowicz E; Duhem S; Somers S; Colin O; Duhamel A; Bordet R
    Eur Neuropsychopharmacol; 2018 Aug; 28(8):925-932. PubMed ID: 30135030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double blind parallel group placebo controlled comparison of sedative and mnesic effects of etifoxine and lorazepam in healthy subjects [corrected].
    Micallef J; Soubrouillard C; Guet F; Le Guern ME; Alquier C; Bruguerolle B; Blin O
    Fundam Clin Pharmacol; 2001 Jun; 15(3):209-16. PubMed ID: 11468032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxonidine and cognitive function: interactions with moclobemide and lorazepam.
    Wesnes K; Simpson PM; Jansson B; Grahnén A; Weimann HJ; Küppers H
    Eur J Clin Pharmacol; 1997; 52(5):351-8. PubMed ID: 9272403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers.
    Allain H; Tessier C; Bentué-Ferrer D; Tarral A; Le Breton S; Gandon M; Bouhours P
    Psychopharmacology (Berl); 2003 Feb; 165(4):419-29. PubMed ID: 12459926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cognitive and psychomotor effects of opioid analgesics. II. A randomized controlled trial of single doses of morphine, lorazepam and placebo in healthy subjects.
    Hanks GW; O'Neill WM; Simpson P; Wesnes K
    Eur J Clin Pharmacol; 1995; 48(6):455-60. PubMed ID: 8582463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cognitive and psychomotor effects of morphine in healthy subjects: a randomized controlled trial of repeated (four) oral doses of dextropropoxyphene, morphine, lorazepam and placebo.
    O'Neill WM; Hanks GW; Simpson P; Fallon MT; Jenkins E; Wesnes K
    Pain; 2000 Mar; 85(1-2):209-15. PubMed ID: 10692620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice.
    Nguyen N; Fakra E; Pradel V; Jouve E; Alquier C; Le Guern ME; Micallef J; Blin O
    Hum Psychopharmacol; 2006 Apr; 21(3):139-49. PubMed ID: 16625522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of single doses of alpidem, lorazepam, and placebo on memory and attention in healthy young and elderly volunteers.
    Satzger W; Engel RR; Ferguson E; Kapfhammer H; Eich FX; Hippius H
    Pharmacopsychiatry; 1990 May; 23 Suppl 3():114-9. PubMed ID: 1974070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cognitive and psychomotor effects of opioid analgesics. I. A randomized controlled trial of single doses of dextropropoxyphene, lorazepam and placebo in healthy subjects.
    O'Neill WM; Hanks GW; White L; Simpson P; Wesnes K
    Eur J Clin Pharmacol; 1995; 48(6):447-53. PubMed ID: 8582462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychomotor effects of the anxiolytic abecarnil: a comparison with lorazepam.
    Hege SG; Ellinwood EH; Wilson WH; Helligers CA; Graham SM
    Psychopharmacology (Berl); 1997 May; 131(2):101-7. PubMed ID: 9201796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers.
    de Haas SL; de Visser SJ; van der Post JP; de Smet M; Schoemaker RC; Rijnbeek B; Cohen AF; Vega JM; Agrawal NG; Goel TV; Simpson RC; Pearson LK; Li S; Hesney M; Murphy MG; van Gerven JM
    J Psychopharmacol; 2007 Jun; 21(4):374-83. PubMed ID: 17092968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial.
    Stein DJ
    Adv Ther; 2015 Jan; 32(1):57-68. PubMed ID: 25620535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers.
    de Haas SL; Franson KL; Schmitt JA; Cohen AF; Fau JB; Dubruc C; van Gerven JM
    J Psychopharmacol; 2009 Aug; 23(6):625-32. PubMed ID: 18635696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers.
    Stonnington CM; Snyder PJ; Hentz JG; Reiman EM; Caselli RJ
    J Clin Psychiatry; 2009 Oct; 70(10):1379-84. PubMed ID: 19573495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of treatment with etizolam 0.5 mg BID on cognitive performance: a 3-week, multicenter, randomized, double-blind, placebo-controlled, two-treatment, three-period, noninferiority crossover study in patients with anxiety disorder.
    De Candia MP; Di Sciascio G; Durbano F; Mencacci C; Rubiera M; Aguglia E; Garavini A; Bersani G; Di Sotto A; Placidi G; Cesana BM
    Clin Ther; 2009 Dec; 31(12):2851-9. PubMed ID: 20110024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers.
    de Haas SL; de Visser SJ; van der Post JP; Schoemaker RC; van Dyck K; Murphy MG; de Smet M; Vessey LK; Ramakrishnan R; Xue L; Cohen AF; van Gerven JM
    J Psychopharmacol; 2008 Jan; 22(1):24-32. PubMed ID: 18187530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and dynamic studies with a new anxiolytic imidazo-pyridine alpidem utilizing pharmaco-EEG and psychometry.
    Saletu B; Grünberger J; Linzmayer L
    Int Clin Psychopharmacol; 1986 Apr; 1(2):145-64. PubMed ID: 2883214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects on postural oscillation and memory functions of a single dose of zolpidem 5 mg, zopiclone 3.75 mg and lormetazepam 1 mg in elderly healthy subjects. A randomized, cross-over, double-blind study versus placebo.
    Allain H; Bentué-Ferrer D; Tarral A; Gandon JM
    Eur J Clin Pharmacol; 2003 Jul; 59(3):179-88. PubMed ID: 12756510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg.
    Wesnes KA; Edgar C; Tretter RN; Bolodeoku J
    Expert Opin Drug Saf; 2009 Nov; 8(6):615-26. PubMed ID: 19747069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lorazepam and scopolamine: A single-dose comparison of effects on human memory and attentional processes.
    Mintzer MZ; Griffiths RR
    Exp Clin Psychopharmacol; 2003 Feb; 11(1):56-72. PubMed ID: 12622344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.